IP Library › Granted Patent US 9,402,835
Granted Patent B2
US 9,402,835 · App. 14/275,031 · Granted Aug 2, 2016

Animal treatments

Inventors: David Rock (Hillsborough, NJ); Mark Ridall (Princeton, NJ)
Assignee: NEWMARKET PHARMACEUTICALS LLC
A61K31/4439A61K9/0053A61K31/135A61K31/137A61K31/155A61K31/341A61K31/403A61K31/4164A61K31/4174A61K31/44A61K31/5415A61K31/635A61K31/7048C07D307/52C07D401/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,402,835
App. No.
14/275,031
Granted
Aug 2, 2016
Kind
B2
Abstract

Compositions and methods for the treatment and control of various conditions in an animal which comprises administering to said animal an effective amount of a immediate release composition of about 0.5% to 50% wt/wt of active ingredient together with excipients to a total of about 100%, wherein said composition dissolves in a relatively short period of time, e.g., 75 seconds or less, 5 seconds or less, or 3 seconds or less, upon administration to said animal.

Claims (4)

1. A method of treating gastric ulcers in an animal in need of said treatment comprising: determining a dose of omeprazole required; administering orally to a pre-gastric mucosa cell of said animal in need of said treatment, a gelatin-based Direct Systemic Introduction (DSI) composition comprising omeprazole; wherein the DSI composition in the animal's oral cavity is dissolved in 30 seconds or less; wherein greater than 50% of the administered omeprazole is absorbed into the animal's circulatory system through the pre-gastric mucosal cells lining the animal's alimentary canal; and wherein the pH of the composition is between 6 and 10.

2. The method of claim 1 , wherein the animal is an equine.

3. A method of suppressing gastric acid in an animal in need of said suppression, comprising: determining a dose of omeprazole required; administering orally to a pre-gastric mucosa cell of said animal in need of said suppression, a gelatin-based Direct Systemic Introduction (DSI) composition comprising omeprazole; wherein the DSI composition in the animal's oral cavity is dissolved in 30 seconds or less; wherein greater than 50% of the administered omeprazole is absorbed into the animal's circulatory system through the pre-gastric mucosal cells lining the animal's alimentary canal; and wherein the pH of the composition is between 6 and 10.

4. The method of claim 3 , wherein the animal is an equine.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2019
From: RIDALL, MARK
To: NEWMARKET PHARMACEUTICALS LLC
Reel/Frame 050714/0569 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PRTY TO NEWMARKET PHARMACEUTICALS LLC AND RECEIVING PRTY TO VETBRIDGE PRODUCT DEVELOPMENT SUBSIDIARY I (NM-OMP), LLC PREVIOUSLY RECORDED ON REEL 047254 FRAME 0898. ASSIGNOR(S) HEREBY CONFIRMS THE THE EXCLUSIVE DISTRIBUTION AND LICENSE AGREEMENT.. Recorded Jul 26, 2019
From: NEWMARKET PHARMACEUTICALS LLC
To: VETBRIDGE PRODUCT DEVELOPMENT SUBSIDIARY I (NM-OMP), LLC
Reel/Frame 049888/0847 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECT THE PATENT NO: PREVIOUSLY RECORDED AT REEL: 046924 FRAME: 0600. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Feb 28, 2019
From: NEWMARKET PHARMACEUTICALS LLC
To: RIDALL, MARK
Reel/Frame 048467/0351 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2018
From: NEWMARKET PHARMACEUTICALS LLC
To: RIDALL, MARK
Reel/Frame 046924/0600 →
EXCLUSIVE DISTRIBUTION AND LICENSE AGREEMENT Recorded Jul 17, 2018
From: VETBRIDGE PRODUCT DEVELOPMENT SUBSIDIARY
To: NEWMARKET PHARMACEUTICALS LLC
Reel/Frame 047254/0898 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2018
From: ROCK, DAVID; RIDALL, MARK
To: NEWMARKET PHARMACEUTICALS, LLC
Reel/Frame 046338/0951 →
CONVERTIBLE PROMISSORY NOTE Recorded Sep 27, 2017
From: NEW MARKET PHARMACEUTICALS, LLC
To: RIDALL, MARK
Reel/Frame 044029/0113 →
LICENSE Recorded Oct 10, 2014
From: NEW MARKET PHARMACEUTICALS, LLC
To: VETBRIDGE PRODUCT DEVELOPMENT SUBSIDIARY I, LLC
Reel/Frame 033930/0226 →
Continuity (4)
Continuation 13343692 · Jan 4, 2012
Provisional Application 61437763 · Jan 31, 2011
Related Publication 20150018391A1 · Jan 15, 2015
Related Publication 20160038473A9 · Feb 11, 2016